Ameliorative effect of a nano chromium metal–organic framework on experimental diabetic chronic kidney disease

Metal–Organic Frameworks (MOFs) are a new class of crystalline porous structures which can be used as a novel structure in diverse fields of medical science. Several studies have shown that chromium supplementation can be effective in amelioration of biochemical parameters of diabetes and its renal...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2021-05, Vol.82 (3), p.393-403
Main Authors: Fakharzadeh, Saideh, Kalanaky, Somayeh, Argani, Hassan, Dadashzadeh, Simin, Torbati, Peyman Mohammadi, Nazaran, Mohammad Hassan, Basiri, Abbas
Format: Article
Language:English
Subjects:
Albumins
Animals
Biomarkers - blood
Chromium
Chromium - pharmacology
Complications
Creatinine
Diabetes
Diabetes mellitus
Diabetes Mellitus, Experimental - drug therapy
diabetic chronic kidney disease
Diabetic Nephropathies - drug therapy
Dietary supplements
Health services
High fat diet
Kidney diseases
Malondialdehyde
Medical science
Medical treatment
Metal-organic frameworks
Metal-Organic Frameworks - chemical synthesis
Metal-Organic Frameworks - pharmacology
nanochelating technology
Nanotechnology
Rats
Streptozocin
Urea
Uric acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metal–Organic Frameworks (MOFs) are a new class of crystalline porous structures which can be used as a novel structure in diverse fields of medical science. Several studies have shown that chromium supplementation can be effective in amelioration of biochemical parameters of diabetes and its renal complications. Therefore, a chromium‐containing MOF (DIFc) was synthetized by nanochelating technology in the present study and then its effect on biochemical indices in diabetic rats was evaluated. Diabetes was induced by high‐fat diet consumption and streptozotocin (35 mg/kg) injection and then the treatment started 8 weeks after disease induction and continued for 8 weeks. The results showed that DIFc treatment decreased HOMA‐IR index, blood urea nitrogen, uric acid and malondialdehyde in plasma samples. This nano MOF also reduced albumin, malondialdehyde and 8‐isoprostane in urine specimen, while it increased creatinine clearance. In conclusion, DIFc MOF demonstrated promising results in the present study, indicating that it can be developed and evaluated in future investigations with the aim of designing a novel agent for management of diabetes and its renal complications.
ISSN:0272-4391
1098-2299
DOI:10.1002/ddr.21759